Molecular Partners AG (MOLN)
Molecular Partners AG at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Molecular Partners AG (MOLN) is a Biotechnology company based in CH with a market capitalization of $145.9M. Free cash flow was negative at -$63.6M. This page tracks MOLN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
CH · 158 employees · IPO Jun 16, 2021
Valuation
Valuation & price
$3.89as of Jul 25, 2026· -24.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$145.9M
Market cap
—
Revenue growth (YoY)
-855.8%
Gross margin
-$63.6M
Free cash flow (USD)
-$89.4M
Net debt
Net cash position
9.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 20, 2026Filing
Clinical Trial Progress
- 6-K filingJul 6, 2026Filing
Clinical Progress Update
- 6-K filingJul 2, 2026Filing
First Patients Dosed
- 6-K filingJun 1, 2026Filing
Presentations at ASCO and SNMMI
- Annual reportMay 12, 2026Filing
Annual Report Filed
- 6-K filingMay 1, 2026Filing
Phase 1 Data Announcement
- 6-K filingApr 14, 2026Filing
Board Proposals Approved
Questions
Frequently asked questions
What is Molecular Partners AG's market cap?
Molecular Partners AG (MOLN) has a market capitalization of $145.9M.
What is MOLN's P/E ratio?
A meaningful P/E ratio is not available for MOLN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Does Molecular Partners AG pay a dividend?
No — MOLN did not pay a dividend in its latest reported fiscal year.
Are insiders buying MOLN stock?
SEC Form 4 filings show no open-market insider buys at Molecular Partners AG in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.